Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7857)	4/17/2000 12:43:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

Cytogen Corp. (CYTO) won't proceed with its planned follow-on offering given recent market volatility and current stock market conditions. The company said rather than withdraw its filing with the Securities and Exchange Commission, it plans to convert the registration statement filed in late March into a shelf registration "in order to enhance the company's ability to move forward more quickly to the extent that market conditions improve." Cytogen filed on March 28, to sell 6 million shares. Cytogen is a biopharmaceutical company. Shares of Cytogen, listed on Nasdaq, fell 1 1/32, or 16.4%, on Friday to 5 1/4. Jim